Metrion and LifeArc extend drug discovery collaboration

The collaboration has now progressed into the hit-to-lead optimisation phase

Metrion Biosciences and LifeArchave announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement, the companies say.

The collaboration is focused on the discovery of novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis. Initially signed in January 2019, the collaboration agreement was extended for the first time in December 2019. Following the achievement of mutually agreed criteria LifeArc has now exercised the option to extend the programme for a further 12 months.

Metrion provides validated ion channel and electrophysiology-based assays and safety profiling services. LifeArc uses its expertise to identify novel modulators of CNS ion channel targets and chemical syntheses, with Metrion evaluating the pharmacological activities of LifeArc compounds using both automated electrophysiology and manual patch clamp technologies.

Dr Edward Stevens, Head of Drug Discovery, Metrion Biosciences, said: “The continued success of our collaboration with LifeArc is testament to the strength of both teams and the long standing and successful research relationship between our companies. The transition to lead optimisation for key chemical series, along with continuation of selected hit-to-lead activities, is very exciting, and I look forward to working together through 2021.”

Dr Justin Bryans, Executive Director, Drug Discovery, LifeArc, commented: “We are delighted to continue our work with Metrion in the field of neuroscience, capitalising on our combined expertise and capabilities to develop potentially life-changing drugs.”

Companies